You are here

Trulicity

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

Endpoints

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Despite Trulicity success, Lilly can't escape diabetes concerns

Despite Trulicity success, Lilly can't escape diabetes concerns

Biopharma Dive

Flag link:

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

Endpoints

Flag link:

Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results

Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results

Endpoints

Flag link:

Trulicity’s turn to show a cardiovascular benefit

Trulicity’s turn to show a cardiovascular benefit

EP Vantage

Flag link:

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Fierce Biotech

Parkinson's Disease

Flag link:

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Flag link:

5 Biggest Blockbuster Diabetes Drugs of the Future

5 Biggest Blockbuster Diabetes Drugs of the Future

Motley Fool

Boehringer Ingelheim

Flag link:

Novo reveals more Ozempic data on change in body weight by baseline BMI

Novo reveals more Ozempic data on change in body weight by baseline BMI

Yahoo/Reuters

Flag link:

Lilly touts Ph3 data for once-weekly Type II diabetes medication

Lilly touts Ph3 data for once-weekly Type II diabetes medication

Drug Delivery Business News

clinical trials

Flag link:

In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug

In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug

Endpoints

clinical trials

Flag link:

Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready

Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready

Fierce Pharma

Flag link:

Lilly's 2018 forecast beats on strength of new drugs

Lilly's 2018 forecast beats on strength of new drugs

Yahoo/Reuters

Flag link:

Novo's experimental diabetes drug likely to compete with Trulicity

Novo's experimental diabetes drug likely to compete with Trulicity

Medical Marketing and Media

Flag link:

Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

Medical Marketing and Media

Flag link:

Novo’s diabetes medication Victoza keeps growing, despite Lilly’s market-share creep

Novo’s diabetes medication Victoza keeps growing, despite Lilly’s market-share creep

Fierce Pharma

Flag link:

Eli Lilly wins label expansion for Trulicity injection with basal insulin

Eli Lilly wins label expansion for Trulicity injection with basal insulin

Endpoints

Flag link:

Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth

Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth

Fierce Pharma

Flag link:

One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign

One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign

Fierce Pharma Marketing

Flag link:

Pages